Home News Insights Trading halts Paper trading Guide Community My account

Market calendarNext market opening

Display in USD

Loading news article.

U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Copyright © WAPE. All rights reserved.

Loading news article.

Gossamer Bio Slides as $250M Financing Hinges on FDA Milestones | WAPE

Newsbenzinga

Gossamer Bio Slides as $250M Financing Hinges on FDA Milestones

Aug 21, 2026, 11:47 ET · Published

Article summary

Gossamer Bio Financing could provide up to $250 million, with much of the funding tied to seralutinib FDA milestones.

An excerpt from the original article.

Related companies

GOSSGOSSView stock

Analyzed by WAPE AI.

Preparing English content…

Comments —

Comment

Loading comments…